nach oben

Erschienen in:

01.09.2009 | Original Article

SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples

verfasst von: Andrew Conroy, David E. Stockett, Duncan Walker, Michelle R. Arkin, Ute Hoch, Judith A. Fox, Rachael Elizabeth Hawtin

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 4/2009

Einloggen, um Zugang zu erhalten

Abstract

Purpose

SNS-032 (formerly BMS-387032) is a potent, selective inhibitor of cyclin-dependent kinases (CDK) 2, 7 and 9, currently in phase 1 clinical trial for chronic lymphocytic leukemia (CLL) and multiple myeloma (MM). We used the MM cell line RPMI-8226 to evaluate the relationship between duration of SNS-032 exposure, target modulation of CDKs 2, 7 and 9, and induction of apoptosis. We also assessed target modulation in patient peripheral blood mononuclear cells (PBMCs) from phase 1 solid tumor patients treated with SNS-032.

Methods

Proliferation and colony forming assays were used to evaluate cytotoxicity, Western blot analyses to evaluate target modulation, FACS analysis to assess cell cycle distribution, RT-PCR to evaluate transcriptional inhibition.

Results

SNS-032 blocks the cell cycle via inhibition of CDKs 2 and 7, and transcription via inhibition of CDKs 7 and 9. Treatment of RPMI-8226 MM cells at 300 nM (IC₉₀) for 6 h was sufficient for commitment to apoptosis. This correlated with inhibition of CDKs 2, 7 and 9, as reflected in substrate signaling molecules. SNS-032 activity was unaffected by human serum. Target modulation was observed in PBMC from treated patients.

Conclusions

These results demonstrate SNS-032 target modulation of CDKs 2, 7 and 9, and establish 6 h exposure as sufficient to commit RPMI-8226 MM cells to apoptosis. Combined with the demonstration of target modulation in PBMC from phase 1 solid tumor patients treated with SNS-032, these data support the ongoing clinical study of SNS-032 in MM and CLL.

Senderowicz AM, Sausville EA (2000) Preclinical and clinical development of cyclin-dependent kinase modulators. J Natl Cancer Inst 92:376–387PubMedCrossRef

Shapiro GI (2006) Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 24:1770–1783PubMedCrossRef

Schwartz GK, Shah MA (2005) Targeting the cell cycle: a new approach to cancer therapy. J Clin Oncol 23:9408–9421PubMedCrossRef

Sharma SV, Fischbach MA, Haber DA, Settleman J (2006) “Oncogenic shock”: explaining oncogene addiction through differential signal attenuation. Clin Cancer Res 12:4392–4395CrossRef

Wickremasinghe RG, Hoffbrand AV (1999) Biochemical and genetic control of apoptosis: relevance to normal hematopoiesis and hematological malignancies. Blood 93:3587–3600PubMed

Belinda C, Baliga SK (2002) Role of Bcl-2 family of proteins in malignancy. Hematol Oncol 20:63–74CrossRef

Wuilleme-Toumi S, Robillard N, Gomez P et al (2005) Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia 19:1248–1252PubMedCrossRef

MacCallum DE, Melville J, Frame S et al (2005) Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of rna polymerase II-dependent transcription and down-regulation of Mcl-1. Cancer Res 65:5399–5407PubMedCrossRef

Derenne S, Monia B, Dean NM et al (2002) Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-xL is an essential survival protein of human myeloma cells. Blood 100:194–199PubMedCrossRef

10.

Nurse P (2002) Nobel Lecture. Cyclin dependent kinases and cell cycle control. Biosci Rep 22:487–499PubMedCrossRef

11.

Morgan DO (1997) Cyclin-dependent kinases: engines, clocks, and microprocessors. Ann Rev Cell Develop Biol 13:261–291CrossRef

12.

Mailand N, Diffley J (2005) CDKs promote DNA replication origin licensing in human cells by protecting Cdc6 from APC/C-dependent proteolysis. Cell 122:915–926PubMedCrossRef

13.

Harper JW, Elledge SJ (1998) The role of Cdk7 in CAK function, a retro-retrospective. Genes Dev 12:285–289PubMedCrossRef

14.

Kaldis P, Russo AA, Chou HS, Pavletich NP, Solomon MJ (1998) Human and yeast Cdk-activating kinases (CAKs) display distinct substrate specificities. Mol Biol Cell 9:2545–2560PubMed

15.

Fesquet D, Morin N, Doree M, Devault A (1997) Is Cdk7/cyclin H/MAT1 the genuine cdk activating kinase in cycling Xenopus egg extracts? Oncogene 15:1303–1307PubMedCrossRef

16.

Akoulitchev S, Makela T, Weinberg R, Reinberg D (1995) Requirement for TFIIH kinase activity in transcription by RNA polymerase II. Nature 377:557–560PubMedCrossRef

17.

Busso D, Keriel A, Sandrock B et al (2000) Distinct regions of MAT1 regulate cdk7 kinase and TFIIH transcription activities. J Biol Chem 275:22815–22823PubMedCrossRef

18.

Hirose Y, Ohkuma Y (2007) Phosphorylation of the C-terminal domain of RNA polymerase II plays central roles in the integrated events of eucaryotic gene expression. J Biochem Tokyo 141:601–608PubMed

19.

Lee TI, Young RA (2000) Transcription of eukaryotic protein-coding genes. Annu Rev Genet 34:77–137PubMedCrossRef

20.

Misra RN, H-y Xiao, Kim KS et al (2004) N-(Cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent. J Med Chem 47:1719–1728PubMedCrossRef

21.

Podar K, Anderson KC (2005) The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood 105:1383–1395PubMedCrossRef

22.

Yasui H, Hideshima T, Richardson P, Anderson K (2006) Recent advances in the treatment of multiple myeloma. Curr Pharm Biotechnol 7:381–393PubMedCrossRef

23.

Frassanito MA, Cusmai A, Iodice G, Dammacco F (2001) Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis. Blood 97:483–489PubMedCrossRef

24.

Chao S-H, Fujinaga K, Marion JE et al (2000) Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J Biol Chem 275:28345–28348PubMedCrossRef

25.

Bach S, Knockaert M, Reinhardt J et al (2005) Roscovitine targets, protein kinases and pyridoxal kinase. J Biol Chem 280:31208–31219PubMedCrossRef

26.

Carlson BA, Dubay MM, Sausville EA, Brizuela L, Worland PJ (1996) Flavopiridol Induces G1 Arrest with Inhibition of Cyclin-dependent Kinase (CDK) 2 and CDK4 in Human Breast Carcinoma Cells. Cancer Res 56:2973–2978PubMed

27.

Losiewicz M, Carlson B, Kaur G, Sausville E, Worland P (1994) Potent inhibition of CDC2 kinase activity by the flavonoid L86–8275. Biochem Biophys Res Commun 201:589–595PubMedCrossRef

28.

McClue S, Blake D, Clarke R et al (2002) In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int J Cancer 102:463–468PubMedCrossRef

29.

Squires MS, Feltell RE, Lock V et al (2007) AT7519, a potent CDK inhibitor, is active in leukemia models and primary CLL patient samples. ASH Annual Meeting Abstracts 110:3127

30.

Chen R, Keating MJ, Gandhi V, Plunkett W (2005) Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. Blood 106:2513–2519PubMedCrossRef

31.

Merino R, Ding L, Veis D, Korsmeyer S, Nunez G (1994) Developmental regulation of the Bcl-2 protein and susceptibility to cell death in B lymphocytes. EMBO J 13:683–691PubMed

32.

Byrd JC, Lin TS, Dalton JT et al (2007) Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 109:399–404PubMedCrossRef

33.

Bible KC, Lensing JL, Nelson SA et al (2005) Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points. Clin Cancer Res 11:5935–5941PubMedCrossRef

34.

Chen R, Wierda WG, Benaissa S et al (2007) Mechanism of Action of SNS–032, a Novel Cyclin Dependent Kinase Inhibitor, in Chronic Lymphocytic Leukemia: Comparison with Flavopiridol. ASH Annual Meeting Abstracts 110:3112

35.

Heath E, Bible K, Martell R, Adelman D, Lorusso P (2008) A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors. Invest New Drugs 26:59–65PubMedCrossRef

36.

Hawtin RE, Cohen R, Haas N et al (2007) In: 12th congress of the European Hematology Association Vienna, Austria, June 7–10, 2007. Haematologica, p 276

37.

Goldberg Z, Wierda W, Chen R et al (2008) In: 13th congress of the European Hematology Association Copenhagen, Denmark, June 12–15, 2008. Haematologica, p 327

38.

Bergsagel P (2007) Individualizing therapy using molecular markers in multiple myeloma. Clin Lymphoma Myeloma 7(Suppl 4):S170–S174PubMedCrossRef

39.

Zhan F, Huang Y, Colla S et al (2006) The molecular classification of multiple myeloma. Blood 108:2020–2028PubMedCrossRef

40.

Ali M, Choy H, Habib A, Saha D (2007) SNS-032 prevents tumor cell-induced angiogenesis by inhibiting vascular endothelial growth factor. Neoplasia 9:370–381PubMedCrossRef

41.

Bergsagel PL, Kuehl WM, Zhan F et al (2005) Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 106:296–303PubMedCrossRef

42.

Trudel S, Sebag M, Li ZH et al (2008) SNS-032, a potent and selective CDK2, 7 and 9 inhibitor, demonstrates preclinical activity in human multiple myeloma. AACR Meeting Abstracts 2008, p 4972

43.

Chiorazzi N, Rai KR, Ferrarini M (2005) Chronic lymphocytic leukemia. N Engl J Med 352:804–815PubMedCrossRef

Titel: SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples
verfasst von: Andrew Conroy
David E. Stockett
Duncan Walker
Michelle R. Arkin
Ute Hoch
Judith A. Fox
Rachael Elizabeth Hawtin
Publikationsdatum: 01.09.2009
Verlag: Springer-Verlag
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 4/2009
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-008-0921-5

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Springer Medizin

SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2009

Phase I study of bryostatin 1, a protein kinase C modulator, preceding cisplatin in patients with refractory non-hematologic tumors

Carbonate and carbamate derivatives of 4-demethylpenclomedine as novel anticancer agents

Pro-apoptotic and cytostatic activity of naturally occurring cardenolides

Indomethacin overcomes doxorubicin resistance by decreasing intracellular content of glutathione and its conjugates with decreasing expression of γ-glutamylcysteine synthetase via promoter activity in doxorubicin-resistant leukemia cells

A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer

MTT assays can underestimate cell numbers

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie